The other side of innovation
Keyword(s):
Government sponsored comparative effectiveness research is the first step towards allowing Uncle Sam to push a restrictive formulary on more and more Americans – with step one in the process being unfettered (and unregulated) communications efforts. Unless we are aware and vigilant, such cost-think may very well lead to a single-payer system referred to in cost-think as “universal coverage†– but in reality will be nothing short of healthcare rationing. There are many dangerous implications, but the most frightening is the chilling effect so-called comparative effectiveness programs will have on the future of healthcare innovation.
2009 ◽
Vol 29
(6)
◽
pp. NP14-NP15
◽
2014 ◽
Vol 3
(2)
◽
pp. 167-176
◽
2012 ◽
Vol 1
(2)
◽
pp. 171-180
◽